Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Aug 17;83(6):826–832. doi: 10.1054/bjoc.2000.1354

Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma

M Johansson 1, R Henriksson 1, A T Bergenheim 2, L-O D Koskinen 2
PMCID: PMC2363533  PMID: 10952789

Abstract

Biotherapy including interleukin-2 (IL-2) treatment seems to be more effective outside the central nervous system when compared to the effects obtained when the same tumour is located intracerebrally. Recently published studies suggest that reduced activity of NK cells in tumour tissue can be increased by histamine. The present study was designed to determine whether IL-2 and histamine, alone or in combination, can induce anti-tumour effects in an orthotopic rat glioma model. One group of rats was treated with histamine alone (4 mg kg–1s.c. as daily injections from day 6 after intracranial tumour implantation), another group with IL-2 alone as a continuous subcutaneous infusion and a third group with both histamine and IL-2. The animals were sacrificed at day 24 after tumour implantation. IL-2 and histamine in combination significantly reduced tumour growth. The microvessel density was significantly reduced, an effect mainly affecting the small vessels. No obvious alteration in the pattern of VEGF mRNA expression was evident and no significant changes in apoptosis were observed. Neither IL-2 nor histamine alone caused any detectable effects on tumour growth. Histamine caused an early and pronounced decline in tumour blood flow compared to normal brain. The results indicate that the novel combination of IL-2 and histamine can be of value in reducing intracerebral tumour growth and, thus, it might be of interest to re-evaluate the therapeutic potential of biotherapy in malignant glioma. © 2000 Cancer Research Campaign

Keywords: IL-2, histamine, glioma, rat, microvascular density, angiogenesis

Full Text

The Full Text of this article is available as a PDF (223.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J. T., Saris S. C., Oldfield E. H. The effect of interleukin-2 on the blood-brain barrier in the 9L gliosarcoma rat model. J Neurosurg. 1989 Jan;70(1):92–96. doi: 10.3171/jns.1989.70.1.0092. [DOI] [PubMed] [Google Scholar]
  2. Asea A., Hermodsson S., Hellstrand K. Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scand J Immunol. 1996 Jan;43(1):9–15. doi: 10.1046/j.1365-3083.1996.d01-14.x. [DOI] [PubMed] [Google Scholar]
  3. Barba D., Saris S. C., Holder C., Rosenberg S. A., Oldfield E. H. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989 Feb;70(2):175–182. doi: 10.3171/jns.1989.70.2.0175. [DOI] [PubMed] [Google Scholar]
  4. Bruce J. N., Criscuolo G. R., Merrill M. J., Moquin R. R., Blacklock J. B., Oldfield E. H. Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. J Neurosurg. 1987 Dec;67(6):880–884. doi: 10.3171/jns.1987.67.6.0880. [DOI] [PubMed] [Google Scholar]
  5. Burtin C., Scheinmann P., Salomon J. C., Lespinats G., Canu P. Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors. Br J Cancer. 1982 Jan;45(1):54–60. doi: 10.1038/bjc.1982.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Caligiuri M. A., Murray C., Robertson M. J., Wang E., Cochran K., Cameron C., Schow P., Ross M. E., Klumpp T. R., Soiffer R. J. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest. 1993 Jan;91(1):123–132. doi: 10.1172/JCI116161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dijkstra C. D., Döpp E. A., Joling P., Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology. 1985 Mar;54(3):589–599. [PMC free article] [PubMed] [Google Scholar]
  8. Dănăilă L., Ghyka G., Ursaciuc C. Interleukin-2 (IL-2) in the treatment of malignant brain tumors (glioblastomas). Rom J Neurol Psychiatry. 1993 Jul-Dec;31(3-4):195–206. [PubMed] [Google Scholar]
  9. Fathallah-Shaykh H. M., Gao W., Cho M., Herrera M. A. Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity. Int J Cancer. 1998 Jan 19;75(2):266–276. doi: 10.1002/(sici)1097-0215(19980119)75:2<266::aid-ijc16>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  10. Fleshner M., Watkins L. R., Redd J. M., Kruse C. A., Bellgrau D. A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats. Cell Transplant. 1992;1(4):307–312. doi: 10.1177/096368979200100408. [DOI] [PubMed] [Google Scholar]
  11. Fontana A., Hengartner H., de Tribolet N., Weber E. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol. 1984 Apr;132(4):1837–1844. [PubMed] [Google Scholar]
  12. Glick R. P., Lichtor T., Mogharbel A., Taylor C. A., Cohen E. P. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery. 1997 Oct;41(4):898–907. doi: 10.1097/00006123-199710000-00025. [DOI] [PubMed] [Google Scholar]
  13. Hayes R. L., Koslow M., Hiesiger E. M., Hymes K. B., Hochster H. S., Moore E. J., Pierz D. M., Chen D. K., Budzilovich G. N., Ransohoff J. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer. 1995 Sep 1;76(5):840–852. doi: 10.1002/1097-0142(19950901)76:5<840::aid-cncr2820760519>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  14. Heiss J. D., Papavassiliou E., Merrill M. J., Nieman L., Knightly J. J., Walbridge S., Edwards N. A., Oldfield E. H. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest. 1996 Sep 15;98(6):1400–1408. doi: 10.1172/JCI118927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hellstrand K., Asea A., Dahlgren C., Hermodsson S. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J Immunol. 1994 Dec 1;153(11):4940–4947. [PubMed] [Google Scholar]
  16. Hellstrand K., Asea A., Hermodsson S. Role of histamine in natural killer cell-mediated resistance against tumor cells. J Immunol. 1990 Dec 15;145(12):4365–4370. [PubMed] [Google Scholar]
  17. Hellstrand K., Hermodsson S. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Int Arch Allergy Appl Immunol. 1990;92(4):379–389. doi: 10.1159/000235169. [DOI] [PubMed] [Google Scholar]
  18. Hellstrand K., Naredi P., Lindner P., Lundholm K., Rudenstam C. M., Hermodsson S., Asztély M., Hafström L. Histamine in immunotherapy of advanced melanoma: a pilot study. Cancer Immunol Immunother. 1994 Dec;39(6):416–419. doi: 10.1007/BF01534430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Henriksson R., Nilsson S., Colleen S., Wersäll P., Helsing M., Zimmerman R., Engman K. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer. 1998 Apr;77(8):1311–1317. doi: 10.1038/bjc.1998.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Henriksson R., Widmark A., Bergh A., Damber J. E. Interleukin-2-induced growth inhibition of prostatic adenocarcinoma (Dunning R3327) in rats. Urol Res. 1992;20(3):189–191. doi: 10.1007/BF00299715. [DOI] [PubMed] [Google Scholar]
  21. Holladay F. P., Lopez G., De M., Morantz R. A., Wood G. W. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells. Neurosurgery. 1992 Apr;30(4):499–505. doi: 10.1227/00006123-199204000-00005. [DOI] [PubMed] [Google Scholar]
  22. Johansson M., Bergenheim A. T., Henriksson R., Koskinen L. O., Vallbo C., Widmark A. Tumor blood flow and the cytotoxic effects of estramustine and its constituents in a rat glioma model. Neurosurgery. 1997 Jul;41(1):237–244. doi: 10.1097/00006123-199707000-00038. [DOI] [PubMed] [Google Scholar]
  23. Johansson S., Landström M., Hellstrand K., Henriksson R. The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. Br J Cancer. 1998 Apr;77(8):1213–1219. doi: 10.1038/bjc.1998.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Joseph I. B., Isaacs J. T. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst. 1998 Nov 4;90(21):1648–1653. doi: 10.1093/jnci/90.21.1648. [DOI] [PubMed] [Google Scholar]
  25. Kruse C. A., Cepeda L., Owens B., Johnson S. D., Stears J., Lillehei K. O. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother. 1997 Oct;45(2):77–87. doi: 10.1007/s002620050405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lillehei K. O., Mitchell D. H., Johnson S. D., McCleary E. L., Kruse C. A. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery. 1991 Jan;28(1):16–23. doi: 10.1097/00006123-199101000-00003. [DOI] [PubMed] [Google Scholar]
  27. Lindgren M., Johansson M., Sandström J., Jonsson Y., Bergenheim A. T., Henriksson R. VEGF and tPA co-expressed in malignant glioma. Acta Oncol. 1997;36(6):615–618. doi: 10.3109/02841869709001324. [DOI] [PubMed] [Google Scholar]
  28. Melder R. J., Koenig G. C., Witwer B. P., Safabakhsh N., Munn L. L., Jain R. K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 1996 Sep;2(9):992–997. doi: 10.1038/nm0996-992. [DOI] [PubMed] [Google Scholar]
  29. Nomura T., Ikezaki K., Matsukado K., Fukui M. Effect of histamine on the blood-tumor barrier in transplanted rat brain tumors. Acta Neurochir Suppl (Wien) 1994;60:400–402. doi: 10.1007/978-3-7091-9334-1_108. [DOI] [PubMed] [Google Scholar]
  30. Saris S. C., Spiess P., Lieberman D. M., Lin S., Walbridge S., Oldfield E. H. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg. 1992 Mar;76(3):513–519. doi: 10.3171/jns.1992.76.3.0513. [DOI] [PubMed] [Google Scholar]
  31. Takai N., Tanaka R., Yoshida S., Hara N., Saito T. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells. Cancer Res. 1988 Apr 15;48(8):2047–2052. [PubMed] [Google Scholar]
  32. Tzeng J. J., Barth R. F., Clendenon N. R., Gordon W. A. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res. 1990 Jul 15;50(14):4338–4343. [PubMed] [Google Scholar]
  33. Weber F., List J., Rommel T., Menzel J., Symas J., Pohl U., Mohr H., Schmitz R., Amue B. Influence of interleukin II on xenotransplanted grade 3 to 4 glioma in nude mice. Strahlenther Onkol. 1989 Jul;165(7):556–558. [PubMed] [Google Scholar]
  34. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol. 1993 Nov;10(4):302–313. [PubMed] [Google Scholar]
  35. Wijsman J. H., Jonker R. R., Keijzer R., van de Velde C. J., Cornelisse C. J., van Dierendonck J. H. A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem. 1993 Jan;41(1):7–12. doi: 10.1177/41.1.7678025. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES